HFpEF is a complex clinical syndrome in which heart is unable to deliver adequate oxygen to the tissues required by the metabolic needs or delivers it at the expense of increased filling pressures despite a normal Ejection Fraction. Multiple comorbid conditions such as diabetes, atrial fibrillation, uncontrolled hypertension, multivessel coronary disease not amenable for intervention, morbid obesity, COPD, pulmonary hypertension, Chronic kidney disease and right heart failure are all contributing to the worsening of HFpEF. No specific treatment in clinical trials has shown to be beneficial in improving outcomes. Hence there is an urgent need to discuss the knowledge gained so far in pathophysiology, biomarkers, comorbidity management, newer therapies in diabetes management, exercise physiology and potential benefits as well as potential newer device therapies and use of technology to improve outcomes.
Goal of this issue:
To summarize the current knowledge in epidemiology, pathogenesis, newer biomarkers of interest in cardiorenal space, differential diagnosis and co management of concurrent conditions, discussion of current knowledge on clinical trials, role of exercise and rehab, and translate evidence from subgroups to gain newer hypothesis in innovative therapies for the future. In addition, in this era of advanced technology, there is an opportunity to discuss utilization of AI, remote technology, and Internet of Things to assess potential benefit in development of newer treatment strategies.
Prof. Dr. Krishnaswami Vijayaraghavan
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.